Business Context and Reporting Period
Company: Inogen, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 8, 2016
Subject: Regulation FD Disclosure regarding Centers for Medicare and Medicaid Services (CMS) Competitive Bidding Round 1 2017 Re-compete results and reimbursement rate announcements.
Key Financial Metrics and Contract Status
This filing does not report specific revenue, profit, or cash flow figures for a fiscal period. Instead, it details projected changes in Medicare reimbursement rates effective January 1, 2017.
- Contract Awards: Inogen received offers for respiratory equipment contracts in 10 of 13 competitive bidding areas.
- Current Holdings: The Company currently holds contracts for 3 of 9 areas under the previous Round 1 Re-compete (effective Jan 1, 2014 – Dec 31, 2016).
- Reimbursement Reductions (Round 1 2017 Re-compete):
- Stationary Oxygen (E1390): Declined ~18.6% ($95.74 to $77.97/month).
- Portable Oxygen Concentrators (E1392): Declined ~5.3% ($38.08 to $36.06/month).
- Total Average Gross Reimbursement (Portable): Expected to drop ~14.8% ($133.82 to $114.03/month).
- Oxygen Tanks (E0431): Declined ~8.8% ($18.99 to $17.32/month), resulting in a ~16.9% total reduction for tank patients.
- Population Impact: Approximately 9% of the Medicare patient population is in Round 1 2017 Re-compete areas. An additional 41% in rural/non-CBA areas will see rates based on regional averages starting Jan 1, 2017.
Material Changes and Operational Impact
The filing outlines significant shifts in the Company's revenue model due to CMS policy changes:
- Non-Contracted Markets: In areas where Inogen does not win contracts, the Company plans to "grandfather" existing patients but will accept lower reimbursement rates starting January 1, 2017.
- Shift to Cash Sales: Inability to offer Medicare coverage in non-contracted markets may lead to higher cash sales and lower rentals for new patients.
- Delivery Model Shift: The reimbursement premium for portable oxygen concentrators versus oxygen tanks is expected to incentivize a shift toward non-delivery technology.
Guidance, Outlook, and Risks
Outlook: CMS is expected to publicly announce contracted suppliers in the fall of 2016. Inogen anticipates potential additional contracts as the process progresses.
Risks and Contingencies:
- Forward-looking statements regarding reimbursement impacts and market shifts are subject to risks and uncertainties.
- Actual results may differ due to CMS rules, competitive bidding assessments, and market acceptance of products.
- Additional risks include supply chain interruptions, intellectual property challenges, and international operations.
Investor Verification Checklist
- Verify the final list of contracted suppliers announced by CMS in the fall of 2016 to confirm the 10 awarded areas.
- Monitor the actual mix of cash sales versus rentals in non-contracted markets post-January 1, 2017.
- Review subsequent 10-Q filings to assess the realized impact of the 14.8% reimbursement reduction on gross margins.
- Confirm the extent of patient "grandfathering" and retention rates in areas where contracts were not won.